GreatNorthCollective/greatnorth-canada-federal-laws-text huggingface dataset:
International Cospas-Sarsat Programme Privileges and Immunities Order — 18
18 Nothing in this Arrangement exempts a Canadian citizen or permanent resident from liability for any taxes or duties imposed by any law in Canada.
International Cospas-Sarsat Programme Privileges and Immunities Order — 19
19 If the Government of Canada considers that an abuse of a privilege or immunity described in this Arrangement has occurred, consultation will take place between the Government of Canada and the Organization in order to determine whether such an abuse has occurred, and, if so, to endeavour to prevent its repetition.
International Cospas-Sarsat Programme Privileges and Immunities Order — 20
20 The Organization will cooperate at all times with the appropriate Canadian authorities to facilitate the proper administration of justice, to secure observance of police regulations and prevent the occurrence of any abuse of the privileges and immunities and facilities referred to in this Arrangement.
International Cospas-Sarsat Programme Privileges and Immunities Order — 21
21 The Secretariat will inform the Minister of Foreign Affairs of the names of Representatives of Member States, Officials posted to Canada, including the Head of Secretariat, and Experts on missions for the Organization, before they take up or relinquish their functions in Canada.
International Cospas-Sarsat Programme Privileges and Immunities Order — 22
22 The Organization is entitled to display the Cospas-Sarsat flag and emblem on its premises and on its vehicles.
International Cospas-Sarsat Programme Privileges and Immunities Order — 23
23 The signatories will resolve any disputes relating to this Arrangement through mutual consultation and negotiation.
International Cospas-Sarsat Programme Privileges and Immunities Order — 24
24 Nothing in this Arrangement will be construed as in any way limiting the right of Canadian authorities to refuse entry into Canada to individuals for reasons of national security, provided that the Organization will be immediately informed in the event that the Government of Canada finds it necessary to take such action in relation to any person enumerated in the Arrangement.
International Cospas-Sarsat Programme Privileges and Immunities Order — 25
25 Privileges and immunities granted in this Arrangement will be granted by the Government of Canada and not by the Governments of the Republic of France, the Russian Federation and the United States of America.
International Cospas-Sarsat Programme Privileges and Immunities Order — 26
26 This Arrangement will not be binding under international law. It will come into effect on the date where both following conditions are fulfilled: (a) the signature of the Arrangement by the four parties; and (b) the publication in the Canada Gazette of the Order in Council recognizing the legal personality of the Organization and granting to it privileges and immunities in Canada.
International Cospas-Sarsat Programme Privileges and Immunities Order — 27
27 This Arrangement may be amended by mutual consent of the signatories.
International Cospas-Sarsat Programme Privileges and Immunities Order — 28
28 This Arrangement can be terminated by the Government of Canada or by the Organization on behalf of the signatories, one year after written notification of intent to terminate is provided.
International Cospas-Sarsat Programme Privileges and Immunities Order — 29
29 Unless terminated in accordance with paragraph 28 above, this Arrangement will remain in effect for as long as the Programme Agreement remains in force and will be automatically terminated at the date the Programme Agreement ceases to be in force.
International Cospas-Sarsat Programme Privileges and Immunities Order — 30
30 Nothing in this Arrangement is intended to conflict with the provisions of the Programme Agreement. In the event of conflict between the provisions of this Arrangement and the Programme Agreement, the provisions of the Programme Agreement will take precedence.
Toronto Port Authority Regulations — a
Her Excellency the Governor General in Council, on the recommendation of the Minister of Transport, pursuant to paragraph 62(1)(b) of the Canada Marine Act a , hereby makes the annexed Toronto Port Authority Regulations . a S.C. 1998, c. 10
Toronto Port Authority Regulations — 1
1 The Toronto Port Authority shall not use, or authorize or permit another person to use, the port to build a bridge or similar fixed link between the mainland of the City of Toronto and the Toronto Islands.
Toronto Port Authority Regulations — 2
2 Section 1 does not apply in respect of a pedestrian tunnel. SOR/2011-200, s. 1
Related Party of a Retail Association Regulations — a
Her Excellency the Governor General in Council, on the recommendation of the Minister of Finance, pursuant to subsection 410(1.1) a and paragraph 463(i.2) b of the Cooperative Credit Associations Act c , hereby makes the annexed Related Party of a Retail Association Regulations . a S.C. 2001, c. 9, s. 315(3) b S.C. 2001, c. 9, s. 339 c S.C. 1991, c. 48
Related Party of a Retail Association Regulations — 1
1 In these Regulations, Act means the Cooperative Credit Associations Act .
Related Party of a Retail Association Regulations — 2
2 For the purpose of subsection 410(1.1) of the Act, a person is not a related party of a retail association if the person would be a related party of the retail association only because the person is (a) a member of the retail association other than a member who (i) controls, or has a significant interest in, the retail association, or (ii) has the right to exercise more than 10% of the votes that may be cast at an annual meeting of the retail association or to appoint or elect more than 10% of the directors of the retail association; (b) a member of an association — other than a member that controls that association — that controls, or has a significant interest in, the retail association; (c) the spouse or common-law partner, or a child who is less than 18 years of age, of a person described in paragraph (a) or (b); or (d) an entity that is controlled, determined without regard to paragraph 3(1)(e) of the Act, by a person described in paragraphs (a) to (c).
Related Party of a Retail Association Regulations — 3
3 These Regulations come into force on the day on which they are registered.
Use of Patented Products for International Humanitarian Purposes Regulations — a
Whereas, pursuant to subsection 21.08(2) a of the Patent Act , the Governor in Council has considered the humanitarian and non-commercial reasons underlying the issuance of authorizations under subsection 21.04(1) a of that Act; a S.C. 2004, c. 23, s. 1
Use of Patented Products for International Humanitarian Purposes Regulations — b
Therefore, Her Excellency the Governor General in Council, on the recommendation of the Minister of Industry, pursuant to section 12 b of the Patent Act , hereby makes the annexed Use of Patented Products for International Humanitarian Purposes Regulations . b S.C. 1993, c. 15, s. 29
Use of Patented Products for International Humanitarian Purposes Regulations — 1
1 In these Regulations, Act means the Patent Act .
Use of Patented Products for International Humanitarian Purposes Regulations — 2
2 (1) Any correspondence and envelope that relate to an application under section 21.04 of the Act shall clearly indicate this fact. The correspondence shall be written in English or French and shall be addressed, together with the envelope, in English or French to the Commissioner. (2) Correspondence shall be delivered to the Patent Office by hand or by mail and (a) if it is delivered during the ordinary business hours of the Patent Office, it is considered to be received by the Commissioner on the day of the delivery; and (b) if it is delivered outside the ordinary business hours of the Patent Office, it is considered to be received on the next business day.
Use of Patented Products for International Humanitarian Purposes Regulations — 4
4 For the purpose of subsection 21.04(2) of the Act, an application for authorization shall be in the form set out in Form 1 of the schedule and shall be signed by the applicant.
Use of Patented Products for International Humanitarian Purposes Regulations — 5
5 (1) The solemn or statutory declaration referred to in paragraph 21.04(3)(c) of the Act shall be in the form set out in Form 2 of the schedule and shall be signed by the applicant. (2) The solemn or statutory declarations referred to in clauses 21.04(3)(d)(i)(A) and (B) and (ii)(A) and (B) of the Act shall be in the form set out in Forms 3, 4, 5 and 6, respectively, of the schedule and shall be signed by the applicant. (3) The solemn or statutory declarations referred to in clauses 21.04(3)(d)(iii)(A), (iv)(A) and (v)(A) of the Act shall be in the form set out in Form 7 of the schedule and shall be signed by the applicant. (4) The solemn or statutory declaration referred to in paragraph 21.16(1)(b) of the Act shall be in the form set out in Form 8 of the schedule and shall be signed by the holder of the authorization.
Use of Patented Products for International Humanitarian Purposes Regulations — 6
6 For the purpose of subsection 21.05(1) of the Act, the authorization shall be in the form set out in Form 9 of the schedule.
Use of Patented Products for International Humanitarian Purposes Regulations — 7
7 For the purpose of section 21.06 of the Act, the website of the holder of an authorization shall disclose the following information: (a) if the pharmaceutical product named in the application is a drug as defined in section 2 of the Food and Drugs Act , the name of the pharmaceutical product as set out in Schedule 1 to the Act and, if applicable, the strength, dosage form and route of administration of the pharmaceutical product, or if the pharmaceutical product is a medical device, the name of the medical device; (b) the name of the country or WTO Member named in the application to which the pharmaceutical product is to be exported; (c) if the country or WTO Member referred to in paragraph (b) is not itself the purchaser of the pharmaceutical product, the name of the person or entity — other than a governmental person or entity — referred to in paragraph 21.04(2)(f) of the Act, to which the product is to be sold, together with their postal address; (d) the quantity of the pharmaceutical product that, under section 21.04 of the Act, has been authorized to be manufactured for export to the country or WTO Member referred to in paragraph (b); (e) the distinguishing features of the pharmaceutical product — including its colour if applicable — and of its label and packaging, as required by regulations made under the Food and Drugs Act ; (f) the name and postal address of the shipping agent and any other party that, to the knowledge of the holder of the authorization, will be handling the pharmaceutical product while it is in transit from Canada to the country or WTO Member referred to in paragraph (b); (g) if the consignee in the importing country or WTO Member is a person or entity other than the country or WTO Member referred to in paragraph (b), or the person or entity referred to in paragraph (c), as the case may be, the name and postal address of the consignee; (h) the quantity of the pharmaceutical product contained in each shipment; (i) the export tracking number issued by the Minister of Health in respect of each shipment; and (j) the number of the bill of lading for each shipment.
Use of Patented Products for International Humanitarian Purposes Regulations — 8
er to which the pharmaceutical product is to be exported and whose name appears in Schedule 4 to the Act, of the numerical ranks on the Index of all of the WTO Members whose names appear both on the Index and in Schedule 4 to the Act; (c) dividing the difference determined under paragraph (b) by the total number of countries listed on the Index; and (d) multiplying the quotient determined under paragraph (c) by 0.04. (6) If the name of the country or WTO Member to which an authorization relates does not appear on the Index, the amount of royalty payable to the patentee or to each of the patentees, as the case may be, shall be determined (a) when there is only one patentee, by multiplying the total monetary value, expressed in Canadian currency, of the agreement pertaining to the pharmaceutical product to be manufactured, sold and exported under the authorization by the royalty rate determined in accordance with subsection (5); and (b) when there is more than one patentee, by dividing the amount determined under paragraph (a) by the number of patentees.
Use of Patented Products for International Humanitarian Purposes Regulations — 9
9 For the purpose of section 21.12 of the Act, an application for the renewal of an authorization shall be in the form set out in Form 10 of the schedule and shall be signed by the holder of the authorization.
Use of Patented Products for International Humanitarian Purposes Regulations — 10
10 The renewal of an authorization by the Commissioner under section 21.12 of the Act shall be in the form set out in Form 11 of the schedule.
Use of Patented Products for International Humanitarian Purposes Regulations — 11
11 For the purpose of paragraph (b) of the definition average price in subsection 21.17(6) of the Act, the publications reporting the prices in Canada of pharmaceutical products sold by or with the consent of the patentee that are equivalent to the pharmaceutical product to which an authorization under section 21.04 of the Act relates are the following: (a) the Ontario Drug Benefit Formulary/Comparative Drug Index published by the Ministry of Health and Long-Term Care of Ontario; (b) the list of insured medications set out in Schedule 1 to the Regulation respecting the List of medications covered by the basic prescription drug insurance plan , CQLR, c. A-29.01, r. 3, as is published under the title “List of Medications” on the website of the Régie de l’assurance maladie du Québec; and (c) the PPS Buyers Guide published by ProActive Pharma Solutions (PPS) or the parts of its website known as PPS Centrus where those prices are set out. SOR/2018-141, s. 2
Use of Patented Products for International Humanitarian Purposes Regulations — Use of Patented Products for International Humanitarian Purposes Regulations
* 12 These Regulations come into force on the day on which An Act to amend the Patent Act and the Food and Drugs Act (The Jean Chrétien Pledge to Africa) , being chapter 23 of the Statutes of Canada, 2004, comes into force. * [Note: Regulations in force May 14, 2005, see SI/2005-46.]
Use of Patented Products for International Humanitarian Purposes Regulations — 1
1 The undersigned hereby applies for an authorization under section 21.04 of the Act.
Use of Patented Products for International Humanitarian Purposes Regulations — 2
2 The pharmaceutical product that the undersigned intends to manufacture and sell for export under the authorization is (a) if the pharmaceutical product is a drug as defined in section 2 of the Food and Drugs Act : ( name of the pharmaceutical product as set out in Schedule 1 to the Act and, if applicable, the strength, dosage form and route of administration of the pharmaceutical product ); or (b) if the pharmaceutical product is a medical device: ( name of the pharmaceutical product as set out in Schedule 1 to the Act, its class, and its identifier within the meaning of section 1 of the Medical Devices Regulations ).
Use of Patented Products for International Humanitarian Purposes Regulations — (a)
(a) if the pharmaceutical product is a drug as defined in section 2 of the Food and Drugs Act : ( name of the pharmaceutical product as set out in Schedule 1 to the Act and, if applicable, the strength, dosage form and route of administration of the pharmaceutical product ); or
Use of Patented Products for International Humanitarian Purposes Regulations — Use of Patented Products for International Humanitarian Purposes Regulations
( name of the pharmaceutical product as set out in Schedule 1 to the Act and, if applicable, the strength, dosage form and route of administration of the pharmaceutical product ); or
Use of Patented Products for International Humanitarian Purposes Regulations — (b)
(b) if the pharmaceutical product is a medical device: ( name of the pharmaceutical product as set out in Schedule 1 to the Act, its class, and its identifier within the meaning of section 1 of the Medical Devices Regulations ).
Use of Patented Products for International Humanitarian Purposes Regulations — Use of Patented Products for International Humanitarian Purposes Regulations
( name of the pharmaceutical product as set out in Schedule 1 to the Act, its class, and its identifier within the meaning of section 1 of the Medical Devices Regulations ).
Use of Patented Products for International Humanitarian Purposes Regulations — 3
3 The maximum quantity of the pharmaceutical product that the undersigned intends to manufacture and sell for export under the authorization is .
Use of Patented Products for International Humanitarian Purposes Regulations — 4
4 For each patented invention to which the application relates, the name(s) of the patentee(s) of the invention, the name(s) and postal address(es) of the representative(s) of the patentee(s) or, if no representative has been appointed, the postal address(es) of the patentee(s), and the patent number(s) issued in respect of the invention are as follows: Name of Patentee Name and Address of Patentee’s Representative or Address of Patentee Patent Number (a) (b) (c) (d)
Use of Patented Products for International Humanitarian Purposes Regulations — 5
5 The name of the WTO Member or country that has notified, respectively, the TRIPS Council or the Government of Canada in writing of its requirement for the pharmaceutical product named in the application, and to which the pharmaceutical product is to be exported, is .
Use of Patented Products for International Humanitarian Purposes Regulations — 6
6 The name, postal address and telephone number of the person or entity referred to in paragraph 21.04(2)(f) of the Act, to which the pharmaceutical product is to be sold, are as follows:
Use of Patented Products for International Humanitarian Purposes Regulations — 7
7 For the purpose of subsection 21.06(1) of the Act, the website address of the undersigned is
Use of Patented Products for International Humanitarian Purposes Regulations — 8
8 The name, postal address and telephone number of the undersigned are as follows:
Use of Patented Products for International Humanitarian Purposes Regulations — (a)
In the matter of an application by ( name of applicant ) for export to ( name of country or WTO Member ) of the following pharmaceutical product: (a) if the pharmaceutical product is a drug as defined in section 2 of the Food and Drugs Act : ( name of the pharmaceutical product as set out in Schedule 1 to the Act and, if applicable, the strength, dosage form and route of administration of the pharmaceutical product ); or (b) if the pharmaceutical product is a medical device: ( name of the pharmaceutical product as set out in Schedule 1 to the Act, its class, and its identifier within the meaning of section 1 of the Medical Devices Regulations );
Use of Patented Products for International Humanitarian Purposes Regulations — (a)
( name of country or WTO Member ) of the following pharmaceutical product: (a) if the pharmaceutical product is a drug as defined in section 2 of the Food and Drugs Act : ( name of the pharmaceutical product as set out in Schedule 1 to the Act and, if applicable, the strength, dosage form and route of administration of the pharmaceutical product ); or (b) if the pharmaceutical product is a medical device: ( name of the pharmaceutical product as set out in Schedule 1 to the Act, its class, and its identifier within the meaning of section 1 of the Medical Devices Regulations );
Use of Patented Products for International Humanitarian Purposes Regulations — (b)
(b) if the pharmaceutical product is a medical device: ( name of the pharmaceutical product as set out in Schedule 1 to the Act, its class, and its identifier within the meaning of section 1 of the Medical Devices Regulations );
Use of Patented Products for International Humanitarian Purposes Regulations — Use of Patented Products for International Humanitarian Purposes Regulations
( name of the pharmaceutical product as set out in Schedule 1 to the Act, its class, and its identifier within the meaning of section 1 of the Medical Devices Regulations );
Use of Patented Products for International Humanitarian Purposes Regulations — 1
1 The undersigned ( name of applicant ) hereby declares, in accordance with paragraph 21.04(3)(c) of the Act, that on ( date ), being at least 30 days before the date of filing of the application for an authorization under section 21.04 of the Act, the undersigned (a) sought from the patentee or, if there is more than one, from each of the patentees, namely, ( name(s) of the patentee(s) ), by certified or registered mail addressed to ( name(s) and postal address(es) of the patentee(s) or the representative(s) of the patentee(s), if any ), a licence to manufacture and sell the pharmaceutical product for export to the country or WTO Member named in the application on reasonable terms and conditions and that such efforts have not been successful; and (b) provided the patentee, or each of the patentees, as the case may be, by certified or registered mail, in the written request for a licence, with the information that is in all material respects identical to the information required under paragraphs 21.04(2)(a) to (g) of the Act.
Use of Patented Products for International Humanitarian Purposes Regulations — (a)
(a) sought from the patentee or, if there is more than one, from each of the patentees, namely, ( name(s) of the patentee(s) ), by certified or registered mail addressed to ( name(s) and postal address(es) of the patentee(s) or the representative(s) of the patentee(s), if any ), a licence to manufacture and sell the pharmaceutical product for export to the country or WTO Member named in the application on reasonable terms and conditions and that such efforts have not been successful; and
Use of Patented Products for International Humanitarian Purposes Regulations — Use of Patented Products for International Humanitarian Purposes Regulations
( name(s) of the patentee(s) ), by certified or registered mail addressed to
Use of Patented Products for International Humanitarian Purposes Regulations — Use of Patented Products for International Humanitarian Purposes Regulations
( name(s) and postal address(es) of the patentee(s) or the representative(s) of the patentee(s), if any ), a licence to manufacture and sell the pharmaceutical product for export to the country or WTO Member named in the application on reasonable terms and conditions and that such efforts have not been successful; and
Use of Patented Products for International Humanitarian Purposes Regulations — (b)
(b) provided the patentee, or each of the patentees, as the case may be, by certified or registered mail, in the written request for a licence, with the information that is in all material respects identical to the information required under paragraphs 21.04(2)(a) to (g) of the Act.
Use of Patented Products for International Humanitarian Purposes Regulations — 2
2 The name, postal address and telephone number of the undersigned are as follows:
Use of Patented Products for International Humanitarian Purposes Regulations — (a)
In the matter of an application by ( name of applicant ) for export to ( name of WTO Member ) of the following pharmaceutical product: (a) if the pharmaceutical product is a drug as defined in section 2 of the Food and Drugs Act : ( name of the pharmaceutical product as set out in Schedule 1 to the Act and, if applicable, the strength, dosage form and route of administration of the pharmaceutical product ); or (b) if the pharmaceutical product is a medical device: ( name of the pharmaceutical product as set out in Schedule 1 to the Act, its class, and its identifier within the meaning of section 1 of the Medical Devices Regulations );